Cytek (CTKB) Chief Legal Officer Ilan Feuchtwang Receives Award

What Happened Ilan Feuchtwang, Cytek Biosciences' Chief Legal Officer and Secretary, was granted two derivative equity awards on August 10, 2026 totaling 368,534 units (241,416 and 127,118). Both grants are reported as awards/acquisitions with a reported acquisition price of $0.00, so no cash changed hands; these are equity compensation grants rather than open‑market purchases or sales.

Key Details

• Transaction date: August 10, 2026; filing date: August 12, 2026 (filed two days after the transaction).
• Reported price: $0.00 for each grant; total reported value $0 (derivative awards).
• Total units granted: 368,534 (241,416 + 127,118).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes of note:
  • F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock.
  • F2: RSU vesting schedule: vest over 4 years with specific tranche timing (see filing) — e.g., 12/48 vest on Aug 18, 2027, with additional tranches on Nov 18, Mar 10, May 18 and Aug 18 in subsequent years, subject to continuous service.
  • F3: A 4‑year option vesting schedule is also included in the filing: 25% vests on Aug 10, 2027, then 1/48 of the shares vests each month thereafter, subject to continuous service.
• Timeliness: Filing date suggests timely reporting (filed two days after the reported transaction date).

Context

• These are equity compensation awards (restricted stock units and/or related derivative awards) that vest over time; RSUs convert into shares only as they vest and typically are subject to forfeiture if the executive leaves before vesting. This is not an open‑market buy or sale, and it does not by itself indicate immediate buying or selling of shares.